关于最近突破性努力的结构视角,以直接对RAS和获得的抗药性进行药物治疗
Jameela Lokhandwala1, Tracess B Smalley1, Timothy H Tran2
1Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
准基斯大鼠肉瘤病毒性coprotein同源 (KRAS) 突变,特别是KRAS G12C和G12D,在治疗非小细胞肺癌等癌症方面显示出前景. 新的抑制剂为以前"无法抗药"的目标提供了希望.
科学领域:
- 在瘤学瘤学.
- 结构生物学 结构生物学
- 药物发现 药物发现 药物发现
背景情况:
- 基尔斯大鼠肉瘤病毒蛋白同源 (KRAS) 突变是癌症的关键驱动因素,历史上被认为是无法治疗的.
- 最近的突破包括FDA批准的对KRAS G12C的共价抑制剂,推进向癌症治疗.
- 在全球范围内,KRAS突变对癌症诊断和死亡率作出了重大贡献.
研究的目的:
- 审查当前KRAS抑制剂的结构生物学.
- 探索针对KRAS突变的策略,包括初级和二级改变.
- 讨论新兴的耐药机制和下一代KRAS抑制剂.
主要方法:
- 对KRAS抑制剂的结构数据的分析.
- 对针对KRAS的向疗法的临床前和临床数据的审查.
- 检查新出现的抗性突变及其结构影响.
主要成果:
- 开发针对KRAS G12C的共价抑制剂和针对KRAS G12D的新型恶性乳素.
- 在临床前模型中,MRTX-1133和BI-2865等非共价抑制剂的有希望的结果.
- 确定克服获得性耐药性和向二次突变的策略.
结论:
- 向KRAS突变已经发生了显著的进化,从无法药物治疗到可药物治疗.
- 下一代抑制剂,包括泛RAS和突变特异性剂,正在彻底改变RAS药物发现.
- 结构生物学见解对于开发有效的KRAS向疗法来对抗抗性的发展至关重要.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:22A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
Published on: June 22, 2015
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Drug Abuse and Addiction: Pharmacological Phenomena
Treatment Resistant Cancers
